Published on 21/12/2025
Setting Up Virtual Visit Technology for Regulatory Compliance
Introduction: Why Technology Setup is Crucial for Virtual Site Visits
As clinical trials increasingly adopt decentralized and remote models, virtual site visits have become central to trial oversight. However, poorly planned technology infrastructure can lead to regulatory violations, data breaches, and failed inspections. The FDA, EMA, and ICH all expect sponsors to validate, document, and secure virtual visit tools in alignment with GCP and Part 11 requirements.
This article presents a step-by-step guide to setting up technology for virtual visits—from selecting compliant platforms to creating audit trails and implementing CAPA when failures occur.
Step 1: Choose a Part 11-Compliant Platform for Remote Visits
The first decision in enabling virtual site visits is selecting a secure and validated video conferencing and document sharing platform. Some commonly used platforms include:
| Platform | Compliance Features | Notes |
|---|---|---|
| Zoom for Healthcare | HIPAA, 21 CFR Part 11, session recording, data encryption | Requires business associate agreement (BAA) |
| Microsoft Teams (Enterprise) | Multi-factor authentication, logging, screen sharing control | Part 11 validation must be documented internally |
| Webex Meetings | Session recording, identity verification, SSO integration | Less commonly used in regulated trials but acceptable |
All tools must be validated with documented user requirements, test
Step 2: Implement Access Control and Secure Login Protocols
Remote monitoring involves sensitive data like eSource, ICFs, and protocol deviation logs. Therefore, secure access policies are critical:
- VPN Access: Limit CRA access to sponsor-approved VPN connections.
- Multi-Factor Authentication (MFA): Required for all remote systems.
- Session Logs: All sessions must generate automatic logs with time stamps and user credentials.
- Temporary Access Windows: Restrict site access to scheduled visit times only.
Secure file sharing tools such as Citrix ShareFile or encrypted SFTP portals can support document exchanges.
Step 3: Validate the Remote Source Data Review Process
Virtual visits often include source data verification (SDV) or source data review (SDR). The following controls should be in place:
- Live screen-sharing sessions without recordings, unless explicitly permitted.
- Use of watermarking and disabling download capabilities for sensitive documents.
- Separate logs listing the reviewed documents and individuals involved in the review.
- Session validation features, such as timestamps and encrypted access logs.
According to the Japanese PMDA, a 2022 inspection cited a sponsor for failing to maintain access logs for SDR sessions conducted over unsecured calls.
Step 4: Integrate Virtual Visit Tools with the eTMF
Inspection readiness depends on seamless integration of virtual visit documentation into the electronic Trial Master File (eTMF). To ensure alignment with regulatory expectations:
- Use standard eTMF artifacts such as 05.04.04 – Monitoring Visit Report (Remote).
- Maintain version-controlled SOPs for virtual visit documentation.
- Upload audit-ready formats (PDF/A) with secure timestamped e-signatures.
- Ensure metadata entry fields include visit type (remote/hybrid), CRA ID, and platform used.
eTMF systems such as Veeva Vault and Wingspan offer structured upload workflows that help in aligning with audit expectations.
Step 5: Train CRAs and Site Personnel on Tech Setup
The success of virtual oversight depends on personnel readiness. Sponsors should ensure CRAs and site staff are trained on:
- Pre-visit readiness checklists covering internet connectivity, document preparation, and platform access.
- Conducting trial runs or test calls before the actual visit.
- Use of approved SOPs and troubleshooting protocols.
- CAPA procedures in the event of session failures or delays.
All training should be documented and tracked through learning management systems (LMS) or training logs.
Case Study: Remote Visit Technology Failure in a Diabetes Trial
Context: A global Phase III diabetes trial employed Microsoft Teams for virtual site visits. One site experienced persistent audio dropouts and connectivity failures.
Regulatory Impact: During an FDA audit, the sponsor was unable to produce logs showing any attempt to correct the issue or reschedule the visit. This resulted in a formal finding and required a retrospective CAPA plan.
Resolution: The sponsor implemented a mandatory site technology verification checklist and added a standard field in the visit report template for documenting technology-related disruptions.
Technology Readiness Checklist for Virtual Visits
| Checklist Item | Status |
|---|---|
| Validated, Part 11 compliant platform selected | Complete |
| VPN and MFA access protocols configured | Complete |
| Documented screen sharing and access logs | Complete |
| CRAs and site staff trained on tools and SOPs | Complete |
| eTMF integrated with report templates and audit trail | Complete |
Conclusion: Inspection-Ready Virtual Visit Infrastructure
Establishing a compliant virtual visit setup involves far more than scheduling a video call. It requires documented validation, role-specific access controls, structured reporting, and proactive CAPA workflows. Regulatory agencies have made it clear that virtual visits must meet the same documentation and oversight standards as on-site monitoring.
With this step-by-step guide, sponsors and CROs can create an inspection-ready framework that aligns with the latest GCP, FDA, and EMA expectations—while enabling flexible, efficient trial monitoring.